Form D · Other

Cascade Prodrug Inc.

Eugene, OR · CIK 0001541764

Offering snapshot reported Apr 8, 2020 · SEC filing

Reported sold
$200K
Offering amount: $3M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 18, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 8, 2020Initial$200,000No comparison4SEC filing
May 7, 2019Amendment$250,000$50,000vs Dec 19, 20172SEC filing
Dec 19, 2017Initial$200,000No comparison1SEC filing
Jun 13, 2016Initial$350,000No comparison7SEC filing
Apr 7, 2015Initial$25,000No comparison1SEC filing
Apr 3, 2013Amendment$1,348,932$202,696vs Aug 3, 201215SEC filing
Aug 3, 2012Initial$1,146,236No comparison11SEC filing
Feb 13, 2012Initial$100,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-364507
Series B Preferred Stock

Source: Form D, filed Apr 8, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Allan Cochrane Director, Executive
Christopher Schelling Director
August Sick Director, Executive
Lynnor Stevenson Director

Issuer details

Industry: Other (See others in industry)

Address:
3342 Antigua Drive
Eugene, OR, 97408